Sign in
Taking people in NetherlandsPhase 1/2

Tests a BOB1 T-cell therapy in adults with returned or resistant B-cell blood cancers

Tests a BOB1 T-cell therapy in adults with B-cell blood cancers that returned.

Key facts

Who runs it
Leids Universitair Medisch Centrum (LUMC)
Where
Leiden, NetherlandsSee the site
Registry title
LUMC-BOB1-B7-TCR.1 in relapsed and refractory B-cell malignancies
Status
Recruiting
Phase
Phase 1/2
People taking part
22 people, planned
Started
5 Jun 2026
Expected to end
1 Sept 2030
Type of study
Interventional
Record updated
9 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a B-cell blood cancer that came back or did not respond, who have no standard treatment left and carry the HLA-B*07:02 tissue type.

Age
18 years or older
Sex
Men and women can join.
Disease stage
B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma or non-Hodgkin B-cell lymphoma that persists or has progressed, with no standard treatment options. ECOG performance status 0-3.
Earlier treatment
No other investigational treatment within 3 months before the infusion. Rules apply for prior T-cell engaging bispecific antibodies and prior CAR therapy.
Biomarker or test result
Positive for HLA-B*07:02 on genotyping. A reliable source of the patient's own CD8 T cells must be available.

Main reasons for not taking part

  • Pregnant or breast feeding women
  • Active infection with HIV, HBV, HCV or HTLV 1/2
  • Active cerebral localization of the B-cell malignancy
  • Active Graft versus Host Disease needing immunosuppression
  • Live vaccine within 6 weeks before treatment

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Disease persistence or progression of B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM) or non-Hodgkin B-cell lymphoma without standard treatment options as judged by the treating clinician and by a board of at least two other hematologists of the LUMC
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-3
  • Negative pregnancy test in women of childbearing potential
  • For fertile men and women, agreement to use highly effective contraceptive methods for the period between screening and 12 months after IMP infusion
  • Disease entity specific inclusion criteria as specified in the trial protocol
  • Age ≥ 18 years
  • Patients must be able to understand and be willing to give signed informed consent
  • Positive for HLA-B*07:02 according to genotyping results
  • Reliable source of autologous CD8 T cells must be available: o At least 0.03 x 109 CD8+ T cells/L in PB or, alternatively, o Cryopreserved leukapheresis material available that meets all qualification prerequisites as defined by the investigational medicinal product dossier (IMPD)
  • No treatment with other investigational therapeutic product within 3 months prior to IMP infusion
  • No treatment with T-cell engaging bispecific antibodies (BsAbs) within 6 months prior to leukapheresis or, alternatively, no treatment with BsAbs within 2 months prior to the projected date of IMP infusion and availability of cryopreserved leukapheresis material for IMP manufacture harvested prior to start of BsAb treatment
  • In patients with prior Chimeric Antigen Receptor (CAR) therapy: no CAR therapy within 6 months prior to leukapheresis and CAR T cells in PB below limit of detection or, alternatively, availability of cryopreserved leukapheresis material harvested prior to CAR therapy and no CAR therapy within 3 months prior to IMP infusion

Who cannot take part

  • Has received vaccination with live vaccines 6 weeks prior to treatment
  • Known hypersensitivity against any drug of the mandatory trial procedures
  • Active infection with HIV, HBV, HCV or HTLV 1/2
  • Active cerebral localization of B-cell malignancy (cerebral involvement in the past is allowed)
  • Active Graft versus Host Disease requiring current immunosuppression
  • Any clinically significant, advanced or unstable disease or inadequate main organ function that may put the patient at increased risk for severe complications of trial participation at the discretion of the investigator
  • Use of systemic immune suppression including, but not limited to: immunosuppressive agents such as cyclosporine or corticosteroids (at an equivalent dose of 0.5 mg prednisone/kg body weight per day, or higher), inhaled corticosteroids and physiological replacement for adrenal insufficiency are allowed
  • Uncontrolled central nervous system disease
  • Uncontrolled life-threatening infections or uncontrolled disseminated intravascular coagulation; however, if these problems resolve, the start of IMP production and treatment can be initiated on a delayed schedule
  • Pregnant or breast feeding women
  • Unwillingness or inability to comply with procedures required in this clinical trial protocol

Where in Netherlands

  • Leids Universitair Medisch Centrum (LUMC)Leiden, NetherlandsTaking people

About the trial

What the trial wants to find out

The objective of this trial is to determine feasibility, safety and efficacy of LUMC-BOB1-B7-TCR.1 treatment in patients positive for Human Leukocyte Antigen (HLA)-B*07:02 with relapsed or refractory B-cell malignancies.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial
Plain-language title
Tests a BOB1 T-cell therapy in adults with returned or resistant B-cell blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
9 February 2026